Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

被引:2438
作者
Iwai, Y
Ishida, M
Tanaka, Y
Okazaki, T
Honjo, T
Minato, N [1 ]
机构
[1] Kyoto Univ, Grad Sch Biostudies, Dept Immunol & Cell Biol, Kyoto 6068501, Japan
[2] Japan Sci & Technol Corp, Grad Sch Med, Dept Med Chem, Kyoto 6068501, Japan
[3] Japan Sci & Technol Corp, PRESTO, Kyoto 6068501, Japan
关键词
D O I
10.1073/pnas.192461099
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
PD-1 is a receptor of the Ig superfamily that negatively regulates T cell antigen receptor signaling by interacting with the specific ligands (PD-L) and is suggested to play a role in the maintenance of self-tolerance. In the present study, we examined possible roles of the PD-1/PD-L system in tumor immunity. Transgenic expression of PD-L1, one of the PD-L, in P815 tumor cells rendered them less susceptible to the specific T cell antigen receptor-mediated lysis by cytotoxic T cells in vitro, and markedly enhanced their tumorigenesis and invasiveness in vivo in the syngeneic hosts as compared with the parental tumor cells that lacked endogenous PD-L. Both effects could be reversed by anti-PD-L1 Ab. Survey of murine tumor lines revealed that all of the myeloma cell lines examined naturally expressed PID-L1. Growth of the myeloma cells in normal syngeneic mice was inhibited significantly albeit transiently by the administration of anti-PD-L1 Ab in vivo and was suppressed completely in the syngeneic PD-1-deficient mice. These results suggest that the expression of PD-L1 can serve as a potent mechanism for potentially immunogenic tumors to escape from host immune responses and that blockade of interaction between PD-1 and PD-L may provide a promising strategy for specific tumor immunotherapy.
引用
收藏
页码:12293 / 12297
页数:5
相关论文
共 25 条
[1]   Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].
Agata, Y ;
Kawasaki, A ;
Nishimura, H ;
Ishida, Y ;
Tsubata, T ;
Yagita, H ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772
[2]  
BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.iy.12.040194.002005
[3]  
Brändle D, 1998, EUR J IMMUNOL, V28, P4010, DOI 10.1002/(SICI)1521-4141(199812)28:12<4010::AID-IMMU4010>3.0.CO
[4]  
2-5
[5]   CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy [J].
Chambers, CA ;
Kuhns, MS ;
Egen, JG ;
Allison, JP .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :565-594
[6]   Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J].
Freeman, GJ ;
Long, AJ ;
Iwai, Y ;
Bourque, K ;
Chernova, T ;
Nishimura, H ;
Fitz, LJ ;
Malenkovich, N ;
Okazaki, T ;
Byrne, MC ;
Horton, HF ;
Fouser, L ;
Carter, L ;
Ling, V ;
Bowman, MR ;
Carreno, BM ;
Collins, M ;
Wood, CR ;
Honjo, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :1027-1034
[7]   ROLE OF BONE-MARROW-DERIVED CELLS IN PRESENTING MHC CLASS I-RESTRICTED TUMOR-ANTIGENS [J].
HUANG, AYC ;
GOLUMBEK, P ;
AHMADZADEH, M ;
JAFFEE, E ;
PARDOLL, D ;
LEVITSKY, H .
SCIENCE, 1994, 264 (5161) :961-965
[8]   Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues [J].
Ishida, M ;
Iwai, Y ;
Tanaka, Y ;
Okazaki, T ;
Freeman, GJ ;
Minato, N ;
Honjo, T .
IMMUNOLOGY LETTERS, 2002, 84 (01) :57-62
[9]   Targeting of tumor cells for human γδ T cells by nonpeptide antigens [J].
Kato, Y ;
Tanaka, Y ;
Miyagawa, F ;
Yamashita, S ;
Minato, N .
JOURNAL OF IMMUNOLOGY, 2001, 167 (09) :5092-5098
[10]   Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model [J].
Kimura, K ;
Nishimura, H ;
Matsuzaki, T ;
Yokokura, T ;
Nimura, Y ;
Yoshikai, Y .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (02) :71-77